ArKal Medical has raised $17.5 million in a series B financing round led by Thomas McNerney & Partners. Existing investors, Delphi Ventures and MedVenture Associates were also significant investors in this round.
Subscribe to our email newsletter
ArKal Medical is developing a novel continuous glucose monitoring system for the management of diabetes. ArKal’s monitoring system is said to be designed to eliminate many of the inconveniences of current glucose monitoring technologies.
Arvind Jina, president and CEO of ArKal Medical, said: “We are extremely pleased to have the support of such a strong group of investors and this latest infusion of capital is a positive endorsement of the company’s team, technology and strategy. With this investment, we will fund the next stage of corporate and product milestones.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.